InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.345 0.01 (2.99%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$105 Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives 23 Nov 2020 10:01AM $1.085 $0.345 fallen by 68.20%
$105 Reinstatement to Official Quotation 10 Nov 2020 2:21PM $0.950 $0.345 fallen by 63.68%
$105 Encouraging Results Against SARS-CoV-2 Virus 10 Nov 2020 2:21PM $0.950 $0.345 fallen by 63.68%
$105 Extension of Voluntary Suspension 10 Nov 2020 10:08AM $0.950 $0.345 fallen by 63.68%
$105 Extension of Voluntary Suspension 9 Nov 2020 10:02AM $0.950 $0.345 fallen by 63.68%
$105 Suspension from Official Quotation 5 Nov 2020 9:34AM $0.950 $0.345 fallen by 63.68%
$105 Trading Halt 3 Nov 2020 9:40AM $0.950 $0.345 fallen by 63.68%
$105 Letter to Shareholders - Annual General Meeting 30 Oct 2020 5:51PM $1.025 $0.345 fallen by 66.34%
$105 Notice of Annual General Meeting/Proxy Form 30 Oct 2020 5:46PM $1.025 $0.345 fallen by 66.34%
$105 Investor Presentation 30 Oct 2020 9:59AM $0.980 $0.345 fallen by 64.80%
$105 Appendix 4C and Activity Report 21 Oct 2020 11:35AM $1.125 $0.345 fallen by 69.33%
$105 HREC Approval to Start Phase I/II Burns Wound Study 16 Oct 2020 9:38AM $1.060 $0.345 fallen by 67.45%
$105 Trading Halt 14 Oct 2020 2:44PM $1.060 $0.345 fallen by 67.45%
$105 Pause in trading 14 Oct 2020 2:15PM $1.060 $0.345 fallen by 67.45%
$105 R&D Incentive Rebate Received 5 Oct 2020 8:29AM $1.080 $0.345 fallen by 68.06%
$105 Change in substantial holding 30 Sep 2020 7:29PM $1.145 $0.345 fallen by 69.87%
$105 Top 20 Shareholders Update 30 Sep 2020 7:28PM $1.145 $0.345 fallen by 69.87%
$105 Appendix 3G 30 Sep 2020 7:28PM $1.145 $0.345 fallen by 69.87%
$105 Cleansing Statement 30 Sep 2020 7:26PM $1.145 $0.345 fallen by 69.87%
$105 Appendix 2A 30 Sep 2020 7:26PM $1.145 $0.345 fallen by 69.87%
$105 Appendix 2A 30 Sep 2020 7:24PM $1.145 $0.345 fallen by 69.87%
$105 Issue of Placement Shares 30 Sep 2020 7:24PM $1.145 $0.345 fallen by 69.87%
$105 2020 Annual General Meeting 30 Sep 2020 7:23PM $1.145 $0.345 fallen by 69.87%
$105 Recce Appoints Michele Dilizia as Chief Scientific Officer 30 Sep 2020 7:22PM $1.145 $0.345 fallen by 69.87%
$105 Murdoch Children's Research Institute, R435 Against H.Pylori 30 Sep 2020 10:26AM $1.140 $0.345 fallen by 69.74%

401 - 425 of 730 results

Page 17 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.